AI Drug Discovery Enters Its Validation Era
IT时报 reports that AI drug discovery is shifting from the speed of generating candidate molecules toward laboratory validation, clinical value, data governance, and regulation. At a forum in Shanghai, deputy director Li Xiangyu of the Shanghai Center for Drug Evaluation described the field as entering a “clinical-first, value-first” stage, while industry executives described the dry-lab and wet-lab validation gap, data scarcity, and the need for human oversight.
The report documents a substantive shift in AI drug discovery priorities toward experimentally validated results, clinical value, traceable data, and accountable human decision-making, with examples from pharmaceutical manufacturers and regulatory programs.

从BIO-FORUM看产业创新与监管科学同频共振|图AI生成作者/IT时报潘少颖编辑/潘少颖孙妍AI制药的风向变了。如果说,前几年,资本和舆论追逐的是“生成分子的速度”,模型参数越大、生成数量越多,故事就越动听。那么现阶段,行业不再问“AI能不能做药”,而是问“AI做的药到哪一步了”。在10月27日举行的“2......
本文来自微信公众号: IT时报 ,作者:潘少颖
从BIO-FORUM看产业创新与监管科学同频共振|图AI生成
作者/IT时报潘少颖
编辑/潘少颖孙妍
#Shanghai Center for Drug Evaluation#Shanghai Municipal Drug Administration#Shanghai Biomedicine Technology Industry Promotion Center#Anthropic#Johnson & Johnson#Shanghai Pharmaceuticals#Hengrui Pharmaceuticals#China National Medical Products Administration#U.S. Food and Drug Administration#European Medicines Agency#International Council for Harmonisation#MGC Pharmaceuticals